Junshi Biosciences, Coherus Share Toripalimab Survival Data In Esophageal Cancer

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc CHRS announced interim results from the Phase 3 JUPITER-06 trial.
Related: Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial.
The trial is evaluating toripalimab in combination with chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC).
The results were presented at the European Society for Medical Oncology (ESMO21) Virtual Conference 2021.
514 patients were randomized to receive toripalimab or placebo combined with paclitaxel plus cisplatin chemotherapy followed by toripalimab or placebo maintenance.
At a prespecified interim analysis on March 22, with a median follow-up of 7.4 and 7.3 months in the two arms, there was a significant improvement in overall survival (OS) for the toripalimab-chemotherapy arm compared to the placebo-chemotherapy arm (HR=0.58).
A Median OS of 17.0 vs. 11.0 months was observed.
One-year OS rates were 66.0% vs.43.7% for the toripalimab-chemotherapy arm compared to the placebo-chemotherapy arm, respectively.
The toripalimab-chemotherapy arm compared to the placebo-chemotherapy arm achieved significant improvement in progression-free survival (PFS).
The Companies plan to file a marketing application to the FDA for the indication in 2022.
Related Link: Junshi Biosciences, Coherus Receive FDA Breakthrough Therapy Status For Toripalimab In Head & Neck Cancer.
Price Action: CHRS stock closed 1.52% higher at $16.03 on Thursday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga